Company Profile

At Novo Nordisk, our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders.

Novo Nordisk is a leading global healthcare company, founded in 1923 and our heritage has given us experience and capabilities that enable us to expand access to our medicines and work to prevent and ultimately cure disease by pioneering scientific breakthroughs.

Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 80 countries and markets its products in around 170 countries. Every day, millions of people all over the world rely on our products.

For more information visit novonordisk.co.uk

Company Profile

At Novo Nordisk, our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders.

Novo Nordisk is a leading global healthcare company, founded in 1923 and our heritage has given us experience and capabilities that enable us to expand access to our medicines and work to prevent and ultimately cure disease by pioneering scientific breakthroughs.

Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 80 countries and markets its products in around 170 countries. Every day, millions of people all over the world rely on our products.

For more information visit novonordisk.co.uk

Adverse event reporting is available below.

This resource page and the materials included have been organised, developed and funded by Novo Nordisk.

Click here to access Rybelsus® (semaglutide tablets) prescribing information

Click here to access Victoza® (liraglutide) prescribing information

Click here to access Ozempic® (semaglutide) prescribing information

ORAL SEMAGLUTIDE (RYBELSUS®) in clinical practice

This promotional video presentation was originally broadcast on 5 November 2020. Please note that the speakers are not able to answer questions from attendees watching the video on-demand.

Resources (For electronic use only)

Adverse Event Reporting

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.

Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0845 6005055). Calls may be monitored for training purposes.

UK20RYB00231

date of preparation: November 2020